BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25499
Abstract: observed during eltrombopag treatment or at the follow-up visits routinely performed 30 days after surgery. As eltrombopag has been associated with occurrence of cataracts in patients with immune thrombocytopenia, and MYH9-RD is a syndromic disorder… read more here.
Keywords: important determinant; determinant vwf; eltrombopag; bmi important ... See more keywords
Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Hematology"
DOI: 10.1007/s12185-020-02971-1
Abstract: Eltrombopag (EPAG) and romiplostim (ROM), thrombopoietin receptor-agonists with demonstrated efficacy against aplastic anemia (AA) in prospective controlled studies, were authorized in Japan for use in adults with aplastic anemia in 2017 and 2019, respectively. So… read more here.
Keywords: anemia; aplastic anemia; eltrombopag; ten patients ... See more keywords
Dysmegakaryopoiesis and Transient Mild Increase in Bone Marrow Blasts in Patients With Aplastic Anemia Treated With Eltrombopag May Be Signs of Hematologic Improvement and Not Portend Clonal Evolution
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Clinical Pathology"
DOI: 10.1093/ajcp/aqac094
Abstract: Abstract Objectives Eltrombopag, a thrombopoietin-receptor agonist, stimulates hematopoiesis in patients with acquired aplastic anemia (AA). Cytomorphologic changes in bone marrow after eltrombopag administration are still unclear. This study examined the effect of eltrombopag on cytomorphologic… read more here.
Keywords: bone marrow; dysmegakaryopoiesis; eltrombopag; hematologic improvement ... See more keywords
Eltrombopag-Associated Acneiform Rash: A Case Report.
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Therapeutics"
DOI: 10.1097/mjt.0000000000001080
Abstract: To the Editor: Eltrombopag is a thrombopoietin mimetic indicated for the treatment of chronic immune thrombocytopenia (ITP).1 Common adverse events associated with eltrombopag include nausea, diarrhea, myalgias, and transaminitis.2 Dermatologic toxicity has been rarely described… read more here.
Keywords: patient; toxicity; case; rash ... See more keywords
Eltrombopag treatment of a dog with idiopathic aplastic pancytopenia
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Veterinary Internal Medicine"
DOI: 10.1111/jvim.15738
Abstract: Abstract Idiopathic aplastic pancytopenia is an uncommon disease in dogs which results in pancytopenia and for which an immune‐mediated etiology is suspected. A small number of affected dogs reported in the veterinary literature have responded… read more here.
Keywords: idiopathic aplastic; eltrombopag; dog idiopathic; aplastic pancytopenia ... See more keywords
An Eltrombopag Red (Plasma) Alert
Sign Up to like & getrecommendations! Published in 2020 at "Acta Haematologica"
DOI: 10.1159/000508599
Abstract: Eltrombopag is a thrombopoietin receptor agonist frequently used to manage immune thrombocytopenia and aplastic anemia. At the high doses used for aplastic anemia, but not the doses used for immune thrombocytopenia, eltrombopag can cause reddish-brown… read more here.
Keywords: red plasma; aplastic anemia; plasma; eltrombopag ... See more keywords
Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and Applied Thrombosis/Hemostasis"
DOI: 10.1177/10760296211005555
Abstract: Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of normally functioning platelet. We aimed to do a systematic review and meta-analysis of currently available published data… read more here.
Keywords: chronic immune; thrombocytopenia; eltrombopag; group ... See more keywords
Comparing Costs and Consequences of Eltrombopag Plus IST Versus IST Alone for First-Line Treatment in Severe Aplastic Anemia: Results from a Responder Analysis
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-115138
Abstract: Background: Severe Aplastic Anemia (SAA) is a rare bone marrow disorder characterized by inadequate levels of peripheral, multi-lineage blood cells. Of the two available first-line treatments for SAA, allogeneic hematopoietic stem cell transplantation is limited… read more here.
Keywords: line; first line; eltrombopag; treatment ... See more keywords
Eltrombopag for Immune Thrombocytopenia in Adult Patients in the Real-World in France. Final Results of the Elextra Study
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-139967
Abstract: Introduction:Eltrombopag has been available in Europe for the treatment of chronic primary immune thrombocytopenia (ITP) since 2010. Since 2019, it has been indicated in patients with primary ITP, lasting 6 months or longer from diagnosis… read more here.
Keywords: platelet count; eltrombopag; immune thrombocytopenia; world ... See more keywords
Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial
Sign Up to like & getrecommendations! Published in 2019 at "Haematologica"
DOI: 10.3324/haematol.2019.223966
Abstract: Patients with inherited thrombocytopenias often require platelet transfusions to raise their platelet count before surgery or other invasive procedures; moreover, subjects with clinically significant spontaneous bleeding may benefit from an enduring improvement of thrombocytopenia. The… read more here.
Keywords: platelet count; eltrombopag; treatment; inherited thrombocytopenias ... See more keywords
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.
Sign Up to like & getrecommendations! Published in 2020 at "Haematologica"
DOI: 10.3324/haematol.2020.260125
Abstract: Approximately 20-50% patients with chronic phase chronic myeloid leukemia (CML-CP) treated with tyrosine kinase inhibitors (TKIs) or with myelofibrosis (MF) treated with ruxolitinib develop grade ≥3 thrombocytopenia needing treatment interruptions and dose reductions. We conducted… read more here.
Keywords: thrombocytopenia; eltrombopag; myeloid leukemia; patients chronic ... See more keywords